Single‐immune checkpoint inhibitors (ICIs) vs chemotherapy alone
QoL · People with advanced non‐small cell lung cancer
Single‐immune checkpoint inhibitors (ICIs) may leads to higher QOL‐C30 GHS/QOL (range 0‐100) ‐ change from baseline to week 15 compared with chemotherapy (low certainty).
1 finding from 1 review
- Single or combined immune checkpoint inhibitors compared to first‐line platinum‐based chemotherapy with or without… 2021 · Cochrane Headline outcomes onlyRR 1.51 [1.08, 2.1]1 study · 297 participantsLow